Conduit Pharmaceuticals Management
Management criteria checks 0/4
Conduit Pharmaceuticals' CEO is Andrew Regan, appointed in Apr 2025, has a tenure of 1.58 years. directly owns 0.006% of the company’s shares, worth €329.27. The average tenure of the management team and the board of directors is 0.5 years and 1.6 years respectively.
Key information
Andrew Regan
Chief executive officer
US$842.1k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 0.006% |
| Management average tenure | less than a year |
| Board average tenure | 1.6yrs |
Recent management updates
Recent updates
CEO
Andrew Regan (57 yo)
no data
Tenure
Dr. Andrew James Regan is founder of Conduit Pharmaceuticals Inc. and serves as Director of Conduit Pharmaceuticals Inc. (Formerly, Murphy Canyon Acquisition Corp.) since September 2023 and also serves as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | no data | no data | 0.0059% € 329.3 | |
| Interim CFO & Director | less than a year | US$692.94k | 0.0033% € 184.0 | |
| Head of Strategy & Licensing | no data | US$617.38k | 0.18% € 9.9k | |
| Chief Scientific Officer | 1.1yrs | no data | no data |
0.5yrs
Average Tenure
53yo
Average Age
Experienced Management: ZK70's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 1.6yrs | no data | 0.0059% € 329.3 | |
| Interim CFO & Director | 1.6yrs | US$692.94k | 0.0033% € 184.0 | |
| Independent Director | less than a year | US$21.00k | 0.28% € 15.5k | |
| Independent Chairman of the Board | 1.6yrs | US$101.50k | 0.68% € 38.2k | |
| Independent Director | no data | US$181.85k | 0.31% € 17.6k |
1.6yrs
Average Tenure
57yo
Average Age
Experienced Board: ZK70's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/27 04:28 |
| End of Day Share Price | 2025/01/28 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Conduit Pharmaceuticals Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.